Self-developed drugs

Zai Lab licenses other companies’ drugs for commercialization in China.

FAST NEWS: Zai Lab’s loss narrows on improved drug sales

The Latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 33.7% to $80.3 million in the second quarter of this year. Looking Up: The company's net product revenue for…
9688.HK ZLAB.US

Recent Articles

RELATED ARTICLES

  1. BRIEF: Yonghe Medical’s loss narrows on improved efficiency
    2279.HK
  2. Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  4. Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  5. Innogen Pharma jostles for a slice of the weight-loss market
  6. After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  7. PegBio aims to bulk up its finances to deliver weight-loss drugs
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva